Merck’s Keytruda fails more prostate and lung cancer PhIII trials
Merck’s cancer drug behemoth, the anti-PD1 Keytruda, has failed two more Phase III trials in the hard-to-treat prostate cancer setting and in a certain lung …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
